J&J

J&J 3Q09

3Q Revenues: $15.1 billion (-5%)

3Q Earnings: $3.3 billion (+1%)

YTD Revenues: $45.3 billion (-7%)

YTD Earnings: $10.0 billion (-2%)

Comments: Worldwide pharmaceutical revenues dropped 14% to $5.2 billion in 3Q09, with currency fluctuation accounting for 2% of that. U.S. pharma revenues dropped 19% to $2.9 billion. For the YTD, worldwide pharma revenues dropped 13% to $16.5 billion (4% from currency), with U.S. drug revenues falling 15% to $9.7 billion. During the quarter, U.S. sales of Topamax fell from $606 million to $72 million. The only major pharmaceutical products to show growth in the quarter were Remicade (+6% to $1.0 billion), Risperdal Consta (+4% to $353 million), and Velcade (+22% to $231 million). New drugs Prezista and Invega were up worldwide 91% to $151 million and 9% to $97 million, respectively.